EU approves Wegovy tablets, Novo Nordisk widens obesity market, Swedish payers face new cost fight

• Wegovy tablets are the first EU-approved pill for weight loss treatment
• The drug contains semaglutide, already sold as an injectable Wegovy
• Eligible patients are adults with obesity and at least one weight-related condition
• The Swedish impact will depend on reimbursement decisions and regional prescribing guidance

The European Commission has approved Wegovy in tablet form, giving Denmark’s Novo Nordisk the first EU-authorised obesity treatment as a pill. Sveriges Radio reports that the tablets contain semaglutide, the same active substance already sold in injectable Wegovy, and are intended for adults with obesity who also have at least one weight-related comorbidity.

The medical change is simple enough: one product category that has until now largely meant weekly injections can now also be offered as a tablet. The commercial change is larger. A pill removes one barrier for patients reluctant to self-inject, gives prescribers another format to work with, and extends Novo Nordisk’s hold over a treatment area where demand has outrun supply and public systems have tried to ration access through reimbursement rules rather than through lack of interest.

That matters in Sweden because approval by Brussels does not settle who gets the drug paid for. Swedish patients can only expect broad access if the Dental and Pharmaceutical Benefits Agency, TLV, and the regions decide the price justifies public reimbursement, and obesity drugs have already exposed how badly that arithmetic fits tax-funded healthcare. A long-term treatment for a large patient group can move quickly from clinical promise to budget problem.

The tablet approval also arrives in a Nordic market where the same company already sets much of the tempo. Novo Nordisk has turned semaglutide into one of Europe’s most valuable pharmaceutical franchises, and each new formulation makes it harder for competitors and public buyers to reset the terms. Denmark collects the export gains; neighbouring health systems get the invoice and the queue management.

For Swedish doctors, the next question is likely to be less whether the drug works than under what conditions it should be prescribed. Regional guidance often narrows access to patients with the highest medical need, especially when treatment costs are high and expected to continue for years. If the tablet is priced close to the injection, the convenience may increase demand faster than it changes eligibility.

For patients, a pill may look like broader access. For the regions that fund care, it is still semaglutide, still chronic treatment, still a large bill spread across a large population. The first EU-approved obesity tablet now exists; the reimbursement file will decide how many Swedes ever see the box.

Källor: Sveriges Radio Ekot